Pertussis/Whooping Cough Therapeutic Pipeline Analysis, 2022 – Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Emerging Therapies | GlaxoSmithKline (Boostrix), Bionet-Asia, GC Pharma

Pertussis/Whooping Cough Therapeutic Pipeline Analysis, 2022 - Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Emerging Therapies | GlaxoSmithKline (Boostrix), Bionet-Asia, GC Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Pertussis/Whooping Cough therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Pertussis/Whooping Cough Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Pertussis Market. 

The Pertussis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pertussis Pipeline Analysis

Pertussis/Whooping Cough Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into emerging therapies for the treatment of Pertussis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pertussis Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pertussis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

Pertussis/Whooping Cough Therapeutics Outlook 

Treatment for Pertussis may be a bit tricky. Hospitalization may be required for infants and young children as they are most vulnerable to this disease. Along with medication, they may need respiratory support and may require continuous observation.

DelveInsight’s Report covers around 10+ products under different phases of clinical development like –

• Late-stage products (Phase III and Phase II/III)

• Mid-stage products (Phase II and Phase I/II)

• Early-stage products (Phase I/II and Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Pertussis Therapeutic Segment:

Pertussis/Whooping Cough Therapeutics Landscape

Globally, about 10+ key companies are developing therapies for Pertussis/Whooping Cough. Currently, Bionet-Asia hast its Pertussis drug candidates in the mid to advanced stage of clinical development.

Some of the key companies in the Pertussis/Whooping Cough Therapeutics Market include

• Bionet-Asia

• GC Pharma

• Serum Institute of India

And many others

Pertussis/Whooping Cough Therapies covered in the report include:

• DTaP: Bionet-Asia

• GC 3111A: GC Pharma

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pertussis Current Treatment Patterns

4. Pertussis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pertussis Late Stage Products (Phase-III)

7. Pertussis Mid-Stage Products (Phase-II)

8. Pertussis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pertussis Discontinued Products

13. Pertussis Product Profiles

14. Key Companies in the Pertussis Market

15. Key Products in the Pertussis Therapeutics Segment

16. Dormant and Discontinued Products

17. Pertussis Unmet Needs

18. Pertussis Future Perspectives

19. Pertussis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Andersen-Tawil Syndrome Market

“Andersen-Tawil Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Andersen-Tawil Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States